35338 Federal Register / Vol. 86, No. 125 / Friday, July 2, 2021 / Notices 

Order 

Pursuant to 28 CFR 0.100(b) and the 

authority vested in me by 21 U.S.C. 

824(a), I hereby revoke DEA Certificate 

of Registration No. FS7068249 issued to 

Spring Valley Family Pharmacy. 

Further, pursuant to 28 CFR 0.100(b) 

and the authority vested in me by 21 

U.S.C. 823(f), I hereby deny any pending 

application of Spring Valley Family 

Pharmacy to renew or modify this 

registration, as well as any other 

pending application of Spring Valley 

Family Pharmacy for additional 

registration in Ohio. This Order is 

effective August 2, 2021. 

D. Christopher Evans, 

Acting Administrator. 

[FR Doc. 2021–14165 Filed 7–1–21; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–829] 

Importer of Controlled Substances 

Application: United States 

Pharmacopeial Convention 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: United States Pharmacopeial 

Convention has applied to be registered 

as an importer of basic class(es) of 

controlled substance(s). Refer to 

Supplemental Information listed below 

for further drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before August 2, 2021. Such persons 

may also file a written request for a 

hearing on the application on or before 

August 2, 2021. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for a hearing must 

be sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All requests for a 

hearing should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/OALJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DPW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.34(a), this 

is notice that on March 24, 2021, United 

States Pharmaceopeial Convention, 

7135 English Muffin Way, Frederick, 

Maryland 21704, applied to be 

registered as an importer of the 

following basic class(es) of controlled 

substance(s): 

Controlled substance Drug code Schedule 

Cathinone ................................................................................................................................................................ 1235 I 

Methcathinone ......................................................................................................................................................... 1237 I 

Methaqualone .......................................................................................................................................................... 2565 I 

Lysergic acid diethylamide ...................................................................................................................................... 7315 I 

4-Methyl-2,5-dimethoxyamphetamine ..................................................................................................................... 7395 I 

3,4-Methylenedioxyamphetamine ............................................................................................................................ 7400 I 

4-Methoxyamphetamine .......................................................................................................................................... 7411 I 

Codeine-N-oxide ...................................................................................................................................................... 9053 I 

Difenoxin .................................................................................................................................................................. 9168 I 

Heroin ...................................................................................................................................................................... 9200 I 

Morphine-N-oxide .................................................................................................................................................... 9307 I 

Norlevorphanol ........................................................................................................................................................ 9634 I 

Methamphetamine ................................................................................................................................................... 1105 II 

Phenmetrazine ........................................................................................................................................................ 1631 II 

Methylphenidate ...................................................................................................................................................... 1724 II 

Amobarbital ............................................................................................................................................................. 2125 II 

Pentobarbital ........................................................................................................................................................... 2270 II 

Secobarbital ............................................................................................................................................................. 2315 II 

Glutethimide ............................................................................................................................................................ 2550 II 

Phencyclidine .......................................................................................................................................................... 7471 II 

ANPP (4-Anilino-N-phenethyl-4-piperidine) ............................................................................................................. 8333 II 

Phenylacetone ......................................................................................................................................................... 8501 II 

Alphaprodine ........................................................................................................................................................... 9010 II 

Anileridine ................................................................................................................................................................ 9020 II 

Cocaine ................................................................................................................................................................... 9041 II 

Dihydrocodeine ........................................................................................................................................................ 9120 II 

Diphenoxylate .......................................................................................................................................................... 9170 II 

Levomethorphan ...................................................................................................................................................... 9210 II 

Levorphanol ............................................................................................................................................................. 9220 II 

Meperidine ............................................................................................................................................................... 9230 II 

Dextropropoxyphene, bulk (non-dosage forms) ...................................................................................................... 9273 II 

Thebaine .................................................................................................................................................................. 9333 II 

Oxymorphone .......................................................................................................................................................... 9652 II 

Noroxymorphone ..................................................................................................................................................... 9668 II 

Alfentinil ................................................................................................................................................................... 9737 II 

Sufentanil ................................................................................................................................................................. 9740 II 

The company plans to import the bulk 

control substances for distribution as 

analytical reference standards to its 

customers for analytical testing of raw 

materials. 

Approval of permit applications will 

occur only when the registrant’s 

business activity is consistent with what 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 86, No. 125 / Friday, July 2, 2021 / Notices 35339 

*A I have made minor, nonsubstantive, 

grammatical changes to the RD. Where I have made 

any substantive changes, omitted language for 

brevity or relevance, or where I have added to or 

modified the ALJ’s opinion, I have bracketed the 

modified language and explained the edit in a 

footnote marked with an asterisk and a letter in 

alphabetical order. 

1ALJ Ex. 1. 

2ALJ Ex. 2. 

3ALJ Ex. 3. 

is authorized under 21 U.S.C. 952(a)(2). 

Authorization will not extend to the 

import of Food and Drug 

Administration-approved or nonapproved finished dosage forms for 

commercial sale. 

William T. McDermott, 

Assistant Administrator. 

[FR Doc. 2021–14210 Filed 7–1–21; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. 19–22] 

Keith A. Jenkins, N.P.; Decision and 

Order 

On February 19, 2020, the Drug 

Enforcement Administration 

(hereinafter, DEA or Government) 

Administrative Law Judge Mark M. 

Dowd (hereinafter, ALJ), issued a 

Recommended Rulings, Findings of 

Fact, Conclusions of Law, and Decision 

(hereinafter, RD) on the action to revoke 

the DEA Certificate of Registration 

Numbers MJ3401609 and MJ4509331 of 

Keith A. Jenkins, N.P. The ALJ 

transmitted the record to me on March 

10, 2020. Having reviewed and 

considered the entire administrative 

record before me, I adopt the ALJ’s RD 

with modifications, where noted 

herein.*A

Order 

Pursuant to 28 CFR 0.100(b) and the 

authority vested in me by 21 U.S.C. 

824(a), I hereby dismiss the Order to 

Show Cause issued to Keith A. Jenkins, 

N.P. I further order that any pending 

applications for renewal of DEA 

Certificates of Registration MJ3401609 

and MJ4509331 be granted. This Order 

is effective immediately. 

D. Christopher Evans, 

Acting Administrator. 

Paul Soeffing, Esq., for the Government 

Robert W. Liles, Esq. and Meaghan K. 

McCormick, Esq., for the Respondent 

Recommended Rulings, Findings of 

Fact, Conclusions of Law, and Decision 

of the Administrative Law Judge 

The Assistant Administrator, 

Diversion Control Division, Drug 

Enforcement Administration (DEA), 

issued an Order to Show Cause (OSC),1

dated April 23, 2019, seeking to revoke 

the Respondent’s Certificates of 

Registration (COR), numbers 

‘‘MJ3401609 and MJ4509331, pursuant 

to 21 U.S.C. 824(a)(5), and deny any 

applications for renewal or modification 

of such registration and any 

applications for any other DEA 

registrations pursuant to 21 U.S.C. 

824(a)(5),’’ because the Respondent has 

been excluded from participation in a 

program pursuant to section 1320a–7(a) 

of Title 42. OSC, at 1. The Respondent 

requested a hearing on May 16, 2019,2

and prehearing proceedings were 

initiated.3 A hearing was conducted in 

this matter on November 20, 2019, at the 

DEA Hearing Facility in Arlington, 

Virginia. 

The issue ultimately to be adjudicated 

by the Acting Administrator, with the 

assistance of this recommended 

decision, is whether the record as a 

whole establishes by a preponderance of 

the evidence that the Respondent’s 

subject registration with the DEA should 

be revoked pursuant to 21 U.S.C. 

824(a)(5). 

After carefully considering the 

testimony elicited at the hearing, the 

admitted exhibits, the arguments of 

counsel, and the record as a whole, I 

have set forth my recommended 

findings of fact and conclusions of law 

below. 

The Allegations 

In the OSC, the Government contends 

that the DEA should revoke the 

Respondent’s DEA COR because he has 

been excluded from participation in a 

program pursuant to section 1320a–7(a) 

of Title 42. 

Specifically, the Government alleges 

the following: 

1. Respondent is registered with the 

DEA as an MLP-nurse practitioner in 

Schedules II through V under DEA 

Certificate of Registration MJ3401609, at 

105 Vanner Rd., Mt. Juliet, TN 37122. 

Respondent is also registered with the 

DEA under DEA Certificate of 

Registration MJ4509331, at 3909 

Woodley Rd., Toledo, OH 43606, with a 

mailing address of 105 Vanner Rd., Mt. 

Juliet, TN 37122. Respondent’s 

registrations both expire by their terms 

on December 31, 2020. Id. Prior to the 

current action, Respondent’s DEA 

Certificates of Registration have not 

been the subject of disciplinary or other 

adverse action by the DEA. 

2. On August 7, 2017, Respondent 

entered an ‘‘Alford Plea of Guilty to a 

Felony’’ to the offense of ‘‘False 

Statement to Medicaid.’’ On August 1l, 

2017, the Circuit Court of Fairfax 

County, Virginia entered its sentencing 

Order for Respondent’s offense of ‘‘False 

Statement for Payment (F)’’ in violation 

of Va. Code Section 32.1–314(F) FRD 

3337F9. See Commonwealth of Virginia 

v. Keith Allen Jenkins, No. FE–2017– 

0000711 (Fairfax Cty. Cir. Ct.). 

3. Based on Respondent’s conviction, 

the U.S. Department of Health and 

Human Services, Office of Inspector 

General (‘‘HHS/OIG’’), by letter dated 

February 28, 2018, mandatorily 

excluded Respondent from participation 

in Medicare, Medicaid and all federal 

health care programs for a minimum 

period of five years pursuant to 42 

U.S.C. 1320a–7(a), effective March 20, 

2018. Notwithstanding the fact that the 

underlying conduct for which the 

Respondent was convicted had no 

nexus to controlled substances, the 

Respondent’s mandatory exclusion from 

Medicare, Medicaid, and all federal 

health care programs by HHS/OIG 

warrants revocation of the Respondent’s 

registration pursuant to 21 U.S.C. 

824(a)(5). See, e.g., Richard Hauser, 

M.D., 83 FR 26308 (2018). 

The Hearing 

Government’s Opening Statement 

The Government outlined its case in 

its Opening Statement. The Government 

seeks the revocation of the Respondent’s 

registrations pursuant to 21 U.S.C. 

824(a)(5), as the Respondent has been 

excluded from a program pursuant to 

§ 1320a–7a of Title 2. Tr. 12. The 

Government explained that in 2017, the 

Respondent entered an Alford plea of 

guilty, to the felony offense of false 

statement to Medicaid, in the Circuit 

Court of Fairfax County, Virginia. On 

the basis of that conviction, in 2018, the 

Department of Health and Human 

Resources, Office of Inspector General 

mandatorily excluded the Respondent 

from participation in Medicare, 

Medicaid and all federal health care 

programs pursuant to 42 U.S.C. 1320a7(a). The Respondent’s exclusion 

remains in effect. Id. 

Respondent’s Opening Statement 

In his Opening Statement, the 

Respondent noted he has stipulated to 

all of the operative facts of the case. Id. 

at 13. The Respondent conceded he was 

convicted as charged, he was excluded 

from participation from Medicare, 

Medicaid and all federal health benefit 

programs, as alleged. Acknowledging 

the evidentiary burden shift to him, 

upon the prima facie showing of these 

facts, the Respondent argued that his 


lotter on DSK11XQN23PROD with NOTICES1